05/19/2026 08:30
Axelspace Announces Launch of Seven GRUS-3 Earth Observation Microsatellites, No Earlier Than July 2026

Axelspace Corporation, a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced today that GRUS-3, a set of seven next-generation Earth observation microsatellites, is scheduled to be launched no earlier than July 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519449959/en/Seven flight model of GRUS-3 next-generation Earth observation microsatellites ©Axel...

AFP launches course on verifying AI-generated content

AFP (Agence France-Presse) has launched a new open-access course designed to help journalists and journalism students detect and verify content generated by artificial intelligence (AI).

AFP (Agence France-Presse) has launched a new open-access course designed to help journalists and journalism students detect and verify content generated by artificial intelligence (AI).
Anglais
05/15/2026 00:00
ACI Worldwide and Security Bank Philippines Set New Benchmark for Enterprise-wide Payments Modernization

ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, and Security Bank Corporation (Security Bank), a leading universal bank in the Philippines, today announced that they won the "Best Payment Technology Initiative in Asia Pacific" at The Asian Banker (TAB) Global Financial Technology Innovation Awards 2026. This award recognizes Security Bank and ACI Worldwide’s transformation of payment infrastructure by consolidating fragmented systems into a unified, scalable p...

05/22/2026 09:18
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 2026

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI),...